Chargement en cours...
Lixisenatide – A New Glucagon-like Peptide 1 Receptor Agonist in the Treatment of Type 2 Diabetes
Optimal glycaemic control is essential to managing risks in patients with type 2 diabetes. However, glycaemic control remains poor among type 2 diabetes patients, particularly the control of post-prandial glucose (PPG). Almost half of patients treated with basal insulin and oral anti-diabetic drugs...
Enregistré dans:
| Publié dans: | Eur Endocrinol |
|---|---|
| Auteur principal: | |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Touch Medical Media
2013
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6003584/ https://ncbi.nlm.nih.gov/pubmed/29922357 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.17925/EE.2013.09.02.76 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|